1. Medtech Insight

US Medicare Agency Ends New Technology Add-On Payments For Some Devices, But May Grant It For Others In 2021

 
• By Sue Darcey

The US Medicare agency will end three new technology add-on payments for devices in 2021 but continue payments for a T2 bacteria panel, and is considering the funding for other assays and devices next year.

Doctor or accounting department writes a note and uses a calculator to calculate expenses - income.

The Centers for Medicare and Medicaid Services (CMS) may grant new technology add-on payments for several medical devices and diagnostics in FY2021, the agency stated in a proposed rule this week. But CMS will end the payments for three devices as their additional funding time expires next year, the agency said.

New technology add-on payments have expired for remedē Systems, a nerve stimulator sponsored by Respicardia Inc.; Sentinel Cerebral Protection System, an embolic protection device manufactured by Claret Medical Inc.; and the Aquabeam Aquablation System used for treatment of lower urinary tract symptoms made by Procept BioRobotics Corp., the agency said in its proposed 2021 inpatient prospective payment system (IPPS)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

SpotitEarly Raised $20.3M In New Funding To Bring AI- And Dog-Sniffing-Powered Early Cancer Detection Test To US

 
• By Marion Webb

Israeli-based SpotitEarly hopes to bring an early cancer-detection test, which uses dogs’ noses to detect compounds in exhaled breath and AI analysis, to US homes in 2026.

Thousands Of Cardiac Digital Twins Reveal Novel Connections With Mental Health

 
• By Natasha Barrow

King’s College London, Imperial College London and The Alan Turing Institute constructed cardiac digital twins at scale, creating over 3,400, in a new study using UK Biobank data published in Nature Cardiovascular Research on 16 May.

China Still ‘Attractive’ For Danaher Despite $50M VBP Drag

 
• By Shubham Singh

Apart from the reimbursement-driven turbulence in diagnostics, other aspects of Danaher’s China business are showing signs of resilience. Patient volumes remain strong and the company does not see evidence that the Chinese government is attempting to actively push Western suppliers out of its healthcare system.